Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lung Non-Squamous Non-Small Cell Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non Small Cell Lung Cancer (3224
)
Lung Adenocarcinoma (592
)
Lung Non-Small Cell Squamous Cancer (104
)
Non Small Cell Lung Cancer (3224
)
Lung Adenocarcinoma (592
)
Lung Non-Small Cell Squamous Cancer (104
)
›
Associations
(133)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
EGFR negative
Lung Non-Squamous Non-Small Cell Cancer
EGFR negative
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: C3 – Early Trials
Cancer Med - 4 days (New C3)
bevacizumab
Sensitive
:
C3
Cancer Med - 4d
bevacizumab
Sensitive: C3 – Early Trials
Cancer Med - 4 days
bevacizumab
Sensitive
:
C3
Cancer Med - 4 days - (New C3)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Innovent Biologics Press Release - 2 weeks (New A1)
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
Innovent Biologics Press Release - 2wk
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Innovent Biologics Press Release - 2 weeks
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
Innovent Biologics Press Release - 2 weeks - (New A1)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks (New B)
sintilimab
Sensitive
:
B
Lancet Respir Med - 3wk
sintilimab
Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks
sintilimab
Sensitive
:
B
Lancet Respir Med - 3 weeks - (New B)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
bevacizumab + erlotinib
Sensitive
:
A1
bevacizumab + erlotinib
Sensitive: A1 - Approval
bevacizumab + erlotinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
toripalimab
Sensitive: A1 - Approval
toripalimab
Sensitive
:
A1
toripalimab
Sensitive: A1 - Approval
toripalimab
Sensitive
:
A1
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
VC
Sensitive: A2 - Guideline
VC
Sensitive
:
A2
VC
Sensitive: A2 - Guideline
VC
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
EP
Sensitive: A2 - Guideline
EP
Sensitive
:
A2
EP
Sensitive: A2 - Guideline
EP
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive: A2 - Guideline
gefitinib
Sensitive
:
A2
gefitinib
Sensitive: A2 - Guideline
gefitinib
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemVin
Sensitive: A2 - Guideline
GemVin
Sensitive
:
A2
GemVin
Sensitive: A2 - Guideline
GemVin
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GT
Sensitive: A2 - Guideline
GT
Sensitive
:
A2
GT
Sensitive: A2 - Guideline
GT
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
carboplatin + pemetrexed
Sensitive: A2 - Guideline
carboplatin + pemetrexed
Sensitive
:
A2
carboplatin + pemetrexed
Sensitive: A2 - Guideline
carboplatin + pemetrexed
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemCarbo
Sensitive: A2 - Guideline
GemCarbo
Sensitive
:
A2
GemCarbo
Sensitive: A2 - Guideline
GemCarbo
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib
Sensitive: A2 - Guideline
erlotinib
Sensitive
:
A2
erlotinib
Sensitive: A2 - Guideline
erlotinib
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login